SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

$TOI
Medical/Nursing Services
Health Care
Get the next $TOI alert in real time by email
SC 13G/A 1 raga20230330_sc13ga.htm SCHEDULE 13G/A raga20230330_sc13ga.htm
 

 



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

____________________

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

_____________________

 

Oncology Institute, Inc.
(Name of Issuer)

 

Class A Common Stock, par value $0.0001
(Title of Class of Securities)

 

23343Q100
(CUSIP Number)

 

March 31, 2023
(Date of Event Which Requires Filling of This Statement)

 

____________________

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐  Rule 13d-1(b)
☒   Rule 13d-1(c)
☐   Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 



 

-1-

 

 

CUSIP No. 23343Q100

(1)

Names of reporting persons:

 

Richy Agajanian

(2)

Check the appropriate box if a member of a group (see instructions):

 

(a) ☐     (b) ☒

(3)

SEC use only

 

(4)

Citizenship or place of organization:

 

United States

Number of

shares

beneficially

owned by

each

reporting

person with:

(5)

Sole voting power:

 

3,312,216

(6)

Shared voting power:

 

253,436

(7)

Sole dispositive power:

 

3,312,216

(8)

Shared dispositive power:

 

253,436

(9)

Aggregate amount beneficially owned by each reporting person:

 

3,565,652

(10)

Check if the aggregate amount in row (9) excludes certain shares (see instructions):

 

(11)

Percent of class represented by amount in row (9):

 

4.8% (Based on 74,551,556 shares issued and outstanding as of March 6, 2023)

(12)

Type of reporting person (see instructions):

 

IN

 

-2-

 

 

CUSIP No. 23343Q100

(1)

Names of reporting persons:

 

Jimmy Holdings, Inc.

(2)

Check the appropriate box if a member of a group (see instructions):

 

(a) ☐      (b) ☒

(3)

SEC use only

 

(4)

Citizenship or place of organization:

 

Delaware

Number of

shares

beneficially

owned by

each

reporting

person with:

(5)

Sole voting power:

 

3,312,216

(6)

Shared voting power:

 

0

(7)

Sole dispositive power:

 

3,312,216

(8)

Shared dispositive power:

 

0

(9)

Aggregate amount beneficially owned by each reporting person:

 

3,312,216

(10)

Check if the aggregate amount in row (9) excludes certain shares (see instructions):

 

(11)

Percent of class represented by amount in row (9):

 

4.4% (Based on 74,551,556 shares issued and outstanding as of March 6, 2022)

(12)

Type of reporting person (see instructions):

 

CO

 

-3-

 

 

Item 1(a) Name of issuer.

 

Oncology Institute, Inc.

 

Item 1(b) Address of issuers principal executive offices.

 

18000 Studebaker Rd, Suite 800

Cerritos, California 90703 

Item 2(a) Name of person filing.

 

(i) Richy Agajanian, MD

 

(ii) Jimmy Holdings, Inc.

 

Item 2(b) Address or principal business office or, if none, residence.

 

The principal business office of Dr. Agajanian is:

 

175 Stephens Hill Road
Reed Point, MT 59069 

 

The principal business office of Jimmy Holdings, Inc. is:

 

175 Stephens Hill Road

Reed Point, MT 59069 

 

Item 2(c) Citizenship or place of organization.

 

Dr. Agajanian is a United States citizen.

 

Jimmy Holdings, Inc. is a Delaware corporation.

 

Item 2(d) Title of class of securities.

 

Class A Common Stock.

 

Item 2(e) CUSIP Number.

 

23343Q100

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

Not applicable

 

Item 4. Ownership.

 

As of the date of this filing, Richy Agajanian, MD beneficially owns 3,565,652 shares of the Issuer’s Class A Common Stock, representing 4.8% of the class of securities based on 74,551,556 shares issued and outstanding as of March 6, 2023. Dr. Agajanian is the sole shareholder, President, and CEO of Jimmy Holdings, Inc., and indirectly holds 3,312,216 of these shares through his ownership of Jimmy Holdings, Inc. Dr. Agajanian is the trustee or co-trustee of three trusts, which trusts collectively hold all of the membership interests of Agajanian Holdings, LLC, which in turn holds the remaining 253,436 shares of Class A Common Stock of the Issuer with respect to which Dr. Agajanian and his co-trustee, if and as applicable, share voting and dispositive power as trustee(s). Dr. Agajanian disclaims beneficial ownership of said 253,436 shares, except to the extent of his pecuniary interest therein as a result of being a beneficiary of one or more of the trusts. 

 

-4-

 

 

Number of shares as to which Richy Agajanian, MD has:

 

(i) Sole power to vote or to direct the vote: 3,312,216

 

(ii) Shared power to vote or to direct the vote: 253,436

 

(iii) Sole power to dispose or to direct the disposition of: 3,312,216

 

(iv) Shared power to dispose or to direct the disposition of: 253,436

 

Number of shares as to which Jimmy Holdings, Inc. has:

 

(i) Sole power to vote or to direct the vote: 3,312,216

 

(ii) Shared power to vote or to direct the vote: 0         

 

(iii) Sole power to dispose or to direct the disposition of: 3,312,216

 

(iv) Shared power to dispose or to direct the disposition of: 0

 

The reporting persons disclaim beneficial ownership of the following securities and the following is included solely for informational purposes. “Business Combination” has the meaning ascribed to such term in the Issuer’s current report on Form 8-K filed with the Securities and Exchange Commission on November 18, 2021. The closing of the Business Combination occurred on November 12, 2021.

 

The reporting persons have the right to receive 731,345 shares of Class A Common Stock in connection with the Business Combination. These shares will be received (i) in the event the Issuer's stock price equals or exceeds (x) $12.50 per share for 20 trading days within any 30 consecutive trading days during the two-year period following the closing of the Business Combination, or (y) $15.00 per share for any 20 trading days within any 30 consecutive trading days during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control.

 

The reporting persons have the right to receive 1,097,018 shares of Class A Common Stock in connection with the Business Combination. These shares will be received (i) in the event the Issuer's stock price equals or exceeds $15.00 per share for any 20 trading days within any 30 consecutive trading days during the three-year period following the closing of the Business Combination, or (ii) in the event of a qualifying change of control.

 

Dr. Agajanian’s spouse holds (i) options representing the right to purchase 869,000 shares of the Issuer’s Class A Common Stock, of which 582,527 are currently vested or will be vested in the next 60 days, (ii) 90,938 restricted shares of the Issuer’s Class A Common Stock subject to forfeiture and unvested until such time the Issuer's stock price reaches $12.50 per share for 20 trading days within any 30 consecutive trading days for the two-year period following the closing of the Business Combination, subject to continued employment at such time, and (iii) 136,407 restricted shares of the Issuer’s Class A Common Stock subject to forfeiture and unvested until such time the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time. Dr. Agajanian has no investment or voting authority with respect to securities held by his spouse and disclaims beneficial ownership thereof.

 

Item 5. Ownership of 5 Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

 

-5-

 

 

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

 

Not applicable

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable

 

Item 9. Notice of Dissolution of Group.

 

Not applicable

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: April 3, 2023

 

 

 

   /s/ Richy Agajanian                                        

Richy Agajanian

   
   
 

Jimmy Holdings, Inc.

 

 

   /s/ Richy Agajanian                                         

Richy Agajanian
President and Chief Executive Officer

 

 

-6-
Get the next $TOI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TOI

DatePrice TargetRatingAnalyst
2/26/2024$2.50Buy
Jefferies
9/14/2022$7.00Buy
Guggenheim
8/15/2022$10.00Buy
Jefferies
More analyst ratings

$TOI
Press Releases

Fastest customizable press release news feed in the world

See more
  • TOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1

    CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents. The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategically located throughout the state. The network is designed to provide comprehensive cancer care that is accessible, affordable, and focused on outcomes for patients and payor partners.

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025

    CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Announces $16.5 million Private Placement

    CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities purchase agreement (the "Securities Purchase Agreement") with accredited investors for a private placement that is expected to result in gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses (the "Private Placement"). The Private Placement includes participation from existing investors, as well as members of the Company's management team and Board of Directors and is expected to close on March

    $TOI
    Medical/Nursing Services
    Health Care

$TOI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TOI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TOI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TOI
SEC Filings

See more

$TOI
Leadership Updates

Live Leadership Updates

See more
  • Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute

    CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Names Jeremy Castle as Chief Operations Officer

    CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Announces Leadership Transition

    CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres

    $TOI
    Medical/Nursing Services
    Health Care

$TOI
Financials

Live finance-specific insights

See more
  • The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025

    CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

    CERRITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, March 25, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Reports Third Quarter 2024 Financial Results

    CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and nine months ended September 30, 2024. Recent Operational Highlights Include 79.9% increase in Dispensary segment revenue compared to prior year quarterWelcomed Rob Carter, as our new Chief Financial Officer3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings to 13 our 2024 newly signed capitation contractsStarted second capitation contract in Florida directly with a health plan

    $TOI
    Medical/Nursing Services
    Health Care

$TOI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more